Literature DB >> 21323997

Systemic lupus erythematosus induced by interferon β1 therapy in a patient with multiple sclerosis.

Dalila Mrabet Bahri1, Hela Khiari, Asma Essouri, Lilia Laadhar, Ines Zaraa, Amel Mrabet, Nihel Meddeb, Slaheddine Sellami.   

Abstract

Drug-induced lupus erythematosus is defined as a lupus-like syndrome temporally related to a drug exposure. We report a 34-year-old woman with multiple sclerosis who developed, while being treated with interferon β-1a, myalgia and associated with wrist synovitis. Clinical and immunologic investigations were in favor of systemic lupus erythematosus. Interferon therapy was maintained. Under corticosteroids and antipaludeen treatment, the patient did not develop any other lupic manifestations.
© 2011 The Authors Fundamental and Clinical Pharmacology © 2011 Société Française de Pharmacologie et de Thérapeutique.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21323997     DOI: 10.1111/j.1472-8206.2011.00929.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  7 in total

1.  Follow-up of hypertension in patients with multiple sclerosis.

Authors:  Seyed Mohammad Baghbanian
Journal:  Iran J Neurol       Date:  2016-07-06

Review 2.  Coexistence of systemic lupus erythematosus and multiple sclerosis. A case report and literature review.

Authors:  Elisa Carolina Jácome Sánchez; María Ariana García Castillo; Victor Paredes González; Fernando Guillén López; Edgar Patricio Correa Díaz
Journal:  Mult Scler J Exp Transl Clin       Date:  2018-04-08

3.  A comprehensive analysis of antigen-specific autoimmune liver disease related autoantibodies in patients with multiple sclerosis.

Authors:  Zisis Tsouris; Christos Liaskos; Efthymios Dardiotis; Thomas Scheper; Vana Tsimourtou; Wolfgang Meyer; George Hadjigeorgiou; Dimitrios P Bogdanos
Journal:  Auto Immun Highlights       Date:  2020-04-10

Review 4.  Side effects of cytokines approved for therapy.

Authors:  Brian A Baldo
Journal:  Drug Saf       Date:  2014-11       Impact factor: 5.606

Review 5.  Myasthenia Gravis: An Acquired Interferonopathy?

Authors:  Cloé A Payet; Axel You; Odessa-Maud Fayet; Nadine Dragin; Sonia Berrih-Aknin; Rozen Le Panse
Journal:  Cells       Date:  2022-04-04       Impact factor: 6.600

6.  Differentiating central nervous system demyelinating disorders: The role of clinical, laboratory, imaging characteristics and peripheral blood type I interferon activity.

Authors:  Dimitris K Karathanasis; Anna Rapti; Adrianos Nezos; Charalampos Skarlis; Constantinos Kilidireas; Clio P Mavragani; Maria Eleftheria Evangelopoulos
Journal:  Front Pharmacol       Date:  2022-08-12       Impact factor: 5.988

7.  Integrative analysis of Multiple Sclerosis using a systems biology approach.

Authors:  Karla Cervantes-Gracia; Holger Husi
Journal:  Sci Rep       Date:  2018-04-04       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.